AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 261 min read$CRL

FOSTER JAMES C sold $8.4M of CRL

FOSTER JAMES C sold 24,042 shares of CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) at $350.00 ($8.41M total) on 2026-10-22 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · FOSTER JAMES C
Published Oct 26, 2026, 8:51 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 26, 2026, 8:55 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CRL
Bearish
medium confidence
Mentioned
$CRL
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CRLBearishLow
01

Why it matters

The director's $8.4M sale reduces his ownership, which may be interpreted as a negative signal by the market.

02

Market read

A material insider sale that could modestly affect CRL's share price in the short term.

03

What to watch

Potential tax planning or diversification motives behind the director's sale.

Relevance 5/10Novelty 6/10Timing: after-market filing today

Background

Form 4 filings disclose insider transactions and are primary sources for insider activity.

Company-level read

Ticker impact

$CRLBearishMedium confidence
Context

Director Foster James C sold 24,042 shares for $8.4M via a Form 4 filing, reducing his stake to 31,596 shares.

Expected impact

likely downward pressure as the market prices in the insider sell

Evidence & confidence

A $8.4M sale by a director is material but not large enough to trigger a sharp move; traders may watch for short-term weakness.

Market effects

Sector

Minimal impact on the broader healthcare services sector; only a single insider transaction.

Regional

U.S. market only; no regional ripple effect.

Global

Low; the filing is company‑specific.

Counterpoint

What could challenge this read

The sale could be unrelated to company fundamentals; price may remain stable.

Key entities

  • Company
    Charles River Laboratories International, Inc.

    Provider of laboratory services and products to the pharmaceutical and biotech industries.

  • Individual
    Foster James C

    Director of Charles River Laboratories who executed the sale.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CRL insider trading history →

Related articles

OCT 21
$CRLHigh

Charles River Labs Stock Climbs As Analysts Boost Targets

Charles River Laboratories (CRL) stock rose 11.27% on strong earnings and analyst upgrades. The company reported $1.00B revenue, $150.8M EBITDA, and $148.62M free cash flow. Analysts raised price targets to $320-$357, citing long-term growth plans and margin expansion. CRL's 'Pathway to Purpose' targets 5-7% revenue CAGR and 24% operating margins by 2030.

stockstotrade.com3 min
OCT 21
$CRLHigh

Charles River (CRL) Stock Climbs As Wall Street Turns Bullish

Charles River Laboratories (CRL) stock rose 8.5% on regulatory relief and bullish sentiment. The company's stock broke out of a $290–$310 range, closing near $343. CRL reported $4.0B in annual revenue, with a 32.7% gross margin. Analysts raised price targets, citing margin expansion and growth plans. The next earnings call is scheduled for November 4, 2026.

timothysykes.com3 min
SEP 24
$CRLHighAI 8/10

Why is Charles River Laboratories stock surging today?

Charles River Laboratories (CRL) stock rose 5.7% to $293.22 after its Investor Day, where it unveiled a 'Pathway to Purpose' strategy and raised its 2026 financial outlook. The company set 2030 targets of 5-7% annual organic revenue growth and a 24% non-GAAP operating margin, while reaffirming and upgrading its 2026 guidance. The move was driven by company-specific developments, as the broader market declined.

investing.com2 min
SEP 17
$CRLMed

Why Charles River Laboratories (CRL) Stock Is Trading Up Today

Charles River Laboratories (CRL) shares rose 3.6% after launching rapid cell banking programs, reducing production time by 40% compared to industry standards. The company aims to improve product quality and regulatory readiness. Shares closed at $281.70, up 3% from the previous close. CRL's stock has seen significant volatility, with a 38.1% gain year-to-date.

financialcontent.com2 min